+966 11 277 7729 Support@pharmaknowl.com Book a call Report Side Effects عربي
PharmaKnowl Consulting Schedule a callRequest a proposal

Articles

How We Develop Regulatory Strategy for the Saudi Market

Mohammed Jobran
Mohammed Jobran

Founder and CEO of PharmaKnowl. Former SFDA Chief Regulatory Pharmacist, with 20+ years of experience in regulatory. Advising the sponsors and MAHs on regulatory…

· Last updated
SFDA Regulatory Strategy

As drug regulations in Saudi Arabia become more stringent and sophisticated each year, biotech and pharmaceutical companies planning to introduce new products to the Saudi market should begin their SFDA drug registration project by developing a robust regulatory affairs strategy (RA Strategy).

The concept of RA Strategy is known by most, mastered by a few. We encounter many who apply the “fix it on the road” strategy, leading to repeated mistakes. Others might even head into the unknown by pivoting their project around the availability of the submission requirements. Such practices ultimately result in high exposure to risk, the least of which is a delayed product launch.

Executive managers would sense when their regulatory project lacks an efficient strategy, typically by noting growing regulatory difficulties along the registration path. The expected risks of a weak RA Strategy range from minor issues that cause repeated additions to timelines and budgets to major, overlooked issues that might engender years of delay, inability to market, or profitability impacts, let alone the total abandonment of projects with complete loss of investment.

Therefore, developing a solid RA Strategy for your product registration is essential to avoid the abovementioned complications. Also, you need to align your regulatory activities with the commercial objectives. Even if your product is eligible for accelerated pathways or designations, it is still axiomatic to establish a reliable RA Strategy to utilize invaluable returns such as:

  • Accurate business decisions
  • Compliance assurance.
  • Smoother market access
  • Measured regulatory impact
  • Shorter launch timelines
  • Controlled budget
  • Investment protection

At PharmaKnowl, we structure our RA Strategy holistically to include all factors that affect it. It is built specifically for the Saudi market with the flexibility to adopt different types of products, centered around the following elements:

  • Company objectives
  • Product Specifications
  • Applicable Regulations
  • Regulatory Intelligence
  • Stakeholders Input

The RA Strategy document will ultimately reflect the outcome of a comprehensive 360-degree regulatory analysis of entities, assets, functions, and marketing phases. Its core should at least incorporate the following:

Within the regulatory strategy, a regulatory plan with a course of action needs to be generated and implemented as part of a regulatory project (Strategy>Plan>Project). The project should include defined deliverables, timelines, task ownership, stakeholders, and implementation methods. Only then will it become a day-to-day regulatory operations mission.

Read More

Scientific Office License Requirements by SFDA

Related service

SFDA Consulting

Former SFDA experts in Riyadh who help you plan, defend and speed up your SFDA submissions.

Mohammed Jobran
About the authorMohammed Jobran
The PharmaKnowl team of regulatory, pharmacovigilance and quality consultants

Who you will work with

The PharmaKnowl Team

Regulatory, pharmacovigilance and quality experts, fully based in our Riyadh office. A senior consultant follows your project from the first call to delivery.

  • 12+Years of experience
  • 2.7kDelivered projects
  • 480+Global clients
Meet the team

Move Forward With a Partner Trusted by Global Life-Science Leaders

Schedule a call or request a tailored proposal from our team.

Trusted by global pharma and rare-disease leaders

PTC Therapeutics logoChiesi logoAlnylam Pharmaceuticals logoSanthera Pharmaceuticals logoAscendis Pharma logoSERB Pharmaceuticals logoImmedica Pharma logo